Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Prostate Cancer Radionuclide Therapy

  • Yiyan Liu
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6797-2

Definition

Radionuclide therapy involves the attempt to kill cancer cells and the surrounding affected tissue with radioactive materials. The advantages of radionuclide therapy include the fact that, depending on the form of treatment, it is either noninvasive or much less invasive than surgery. Bone-seeking radiopharmaceuticals or radionuclides are used to treat prostate cancer if it has spread to the bones. The drug is injected intravenously and is absorbed into the bones. It is a single outpatient treatment that can be administered in the doctor’s office.

Characteristics

Bone metastases are the most common cause of pain in advanced prostate cancer patients resulting from tumor infiltration and extension of the periosteal membranes, mechanical instability, tumor-induced cytokines, stimulating factors, and tumor spread from the bone to contiguous neurological structures. The management of bone pain continues to be a major therapeutic challenge and involves a multidisciplinary...

Keywords

Radionuclide Therapy Beta Particle Penetration Range Shared Toilet Bone Pain Palliation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Coleman R (2016) Treatment of metastatic bone disease and the emerging role of radium-223. Semin Nucl Med 46:99–104CrossRefPubMedGoogle Scholar
  2. Dy SM, Asch SM, Nacim A (2008) Evidence-based standard for cancer pain management. J Clin Oncol 26:3879–3885CrossRefPubMedGoogle Scholar
  3. Hillegonds DJ, Franklin S, Shelton DK, Vijayakumar S, Vijayakumar V (2007) The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc 99:785–794PubMedPubMedCentralGoogle Scholar
  4. Jadvar H (2015) Posiron emission tomography in prostate cancer: summary of systematic reviews and meta-analysis. Tomography 1:18–22CrossRefPubMedPubMedCentralGoogle Scholar
  5. Koo PJ, Kwak JJ, Pokharel S, Choyke PL (2015) Novel imaging of prostate cancer with MRI, MRI/US, and PET. Curr Oncol Rep 17:56CrossRefPubMedGoogle Scholar
  6. Lawrentschuk N, Davis ID, Bolton DM, Scott AM (2007) Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. Int J Urol 14:89–95CrossRefPubMedGoogle Scholar
  7. Nilsson S (2016) Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer. Curr Oncol Rep 18:14CrossRefPubMedPubMedCentralGoogle Scholar
  8. Paes FM, Serafini AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 40:89–104CrossRefPubMedGoogle Scholar
  9. Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germa JR, O’Bryan-Tear CG et al (2013) A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63:189–197CrossRefPubMedGoogle Scholar
  10. Rossi PJ, Schuster DM (2015) Molecular imaging of advanced prostate cancer. Curr Probl Cancer 39:29–32CrossRefPubMedGoogle Scholar
  11. Serafini AN (2001) Therapy of metastatic bone pain. J Nucl Med 42:895–906PubMedGoogle Scholar

See Also

  1. (2012) Cytopenia. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1056. doi: 10.1007/978-3-642-16483-5_1484Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of RadiologyNew Jersey Medical School, Rutgers UniversityNew BrunswickUSA